aspirin / Generic mfg. - LARVOL DELTA

Predictors of adverse pregnancy outcomes in systemic lupus erythematosus: A retrospective cohort study. (PubMed, Clin Rheumatol) - "Standardized monitoring of renal dysfunction (proteinuria, BUN), strict control of disease activity, and protocolized thromboprophylaxis (LDA/LMWH) should be prioritized to mitigate APOs risks in SLE pregnancies. Key Points • Urinary protein positivity is a pan-predictor of adverse pregnancy outcomes (APOs); multivariate analyses show proteinuria ≥ 1 + correlates with higher risks of preterm birth and cesarean delivery. • Elevated blood urea nitrogen (BUN) universally predicts low birth weight (LBW), preterm birth, and cesarean delivery in univariate analyses. • A higher SLEDAI-2K score links to increased risks of LBW, preterm birth, and cesarean delivery (univariate analysis) and independently predicts LBW (multivariate analysis). • Non-use of thromboprophylaxis-especially LMWH-significantly raises miscarriage risk."

Adverse events • Journal • Retrospective data • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease • Systemic Lupus Erythematosus

(5,3) SWCNT-doping phosphorus-magnesium: Difference in adsorption of cardiovascular drugs. (PubMed, J Mol Graph Model) - "The adsorption of hydrochlorothiazide and aspirin drugs onto a phosphorus (P) -magnesium (Mg) -doped (5,3) single-walled carbon nanotube (SWCNT) is investigated by density-functional theory (DFT) calculations using the Vienna Ab initio Simulation Package (VASP). The results manifest the importance of the selected dopant atoms on the modification of the material surface in order to change the adsorption properties and the release conditions. We corroborate the results by means of electronic structure, density of states (DOS), frontier orbitals, and molecular electrostatic potential analysis."

Journal • Cardiovascular

De-Escalation of Low-Dose Aspirin for Primary Prevention in Patients > 75 Years Old (ASHP 2025) - No abstract available

Clinical

Evaluating the Impact of Universal Low-Dose Aspirin Prophylaxis on Preeclampsia Rates at a Federally Qualified Health Center (ASHP 2025) - No abstract available

Gynecology

Composite Bleeding Outcomes with Oral P2Y12 Inhibitors and Aspirin Post Percutaneous Coronary Intervention (ASHP 2025) - No abstract available

Immune globulin and aspirin utilization in Kawasaki disease at Wellstar Medical College of Georgia (ASHP 2025) - No abstract available

An Aspirin Compounded Oral Liquid for Patients with Difficulty Swallowing (ASHP 2025) - No abstract available

Clinical

Evaluation of the Inappropriate Use of Aspirin for Primary Prevention of Cardiovascular Disease Among Older Adults In an Outpatient Veterans Affairs Population (ASHP 2025) - No abstract available

Clinical • Cardiovascular

Concomitant Oral Anticoagulation and Aspirin: A Description of Current Co-Prescribing and Evaluation of Procedures at White City VA Medical Center (ASHP 2025) - No abstract available

Networking Session: Cardiology (ASHP 2025) - "Hosted by the Section of Clinical Specialists and Scientists Discussion Topics: Emerging statistical methods and trial designs in cardiology studies De-prescription of aspirin Education of pharmacy learners about reading and interpreting cardiac imaging/studies Stewardship of higher-cost"

Cardiovascular

Antiphospholipid syndrome presents with aortic thrombosis and central venous catheter-related thrombosis: a case report. (PubMed, Thromb J) - "This case highlights the challenges in timely diagnosing APS and the management complexity of rapid, postoperative thrombus formation. Clinicians should maintain a high index of suspicion for early postoperative hypercoagulability-even when routine coagulation screens are unrevealing-escalate promptly when CVC removal meets resistance, and consider APS-tailored antithrombotic strategies. The possibility that fibrin sheaths and catheter-associated thrombosis can evolve quickly, even after short indwelling times, warrants vigilance and early multidisciplinary intervention. It also raises concern that, in this context, standard direct oral anticoagulants (DOACs) may be less effective."

Journal • Cardiovascular • Genetic Disorders • Hematological Disorders • Immunology • Thrombosis

Evaluation of bromadiolone combined with ciprofloxacin, vitamin D, aspirin, and cinnamon as an apoptosis-mediated rodenticide strategy. (PubMed, Sci Rep) - "Findings suggest that certain additives, particularly cinnamon and aspirin, potentiate oxidative stress and apoptosis, correlating with increased mortality and liver damage. Overall, the integration with existing literature on vitamin K antagonism, cholecalciferol-induced hypercalcemia, NSAID-mediated apoptosis, and coumarin derivatives highlights the study's mechanistic grounding and translational relevance."

Journal • Endocrine Disorders • Metabolic Disorders • CDKN1A

Gut Bacterium Lysinibacillus Sphaericus Exacerbates Aspirin-induced Intestinal Injury by Production of Carboxylesterase EstB. (PubMed, Adv Sci (Weinh)) - "Importantly, inhibition of microbial EstB with the dietary compound flavanomarein abrogated aspirin biotransformation and prevented intestinal injury. Together, these findings reveal L. sphaericus and EstB as central drivers of aspirin enterotoxicity, highlight the functional importance of gut microbiota in drug metabolism, and suggest microbiota- and metabolite-guided precision prevention strategies."

Journal

Abstract: Maternal and fetal outcomes of pregnancy in essential thrombocythemia: A systematic review. (ASH 2025) - "Eligible studies were retrospective cohort studies and case reports of pregnant women with ET receiving aspirin (ASA), interferon (IFN), low-molecular weight heparin (LMWH), or no treatment...This would improve patient-cantered outcomes as well as aid in investigation of population-specific risk factors and the socio-economic factors influencing pregnancy outcomes in ET. The complexity of ET in pregnancy and pregnancy planning, necessitates comprehensive, collaborative cross-disciplinary care and research."

Review • Cardiovascular • Essential Thrombocythemia • Hematological Disorders • Myeloproliferative Neoplasm • Obstetrics • Thrombocytosis • Thrombosis

Outcomes of venous thromboembolism in multiple myeloma: A nationwide analysis of anticoagulation strategies (ASH 2025) - "The current guideline from ASH has a conditional recommendation regarding the use of anticoagulation for VTE prophylaxis in ambulatory patients with MM receiving lenalidomide-, thalidomide-, or pomalidomide-based regimens. Conclusion MM patients who developed VTE without any prophylactic antithrombotic therapy experienced worse outcomes, including longer hospitalizations, higher healthcare costs, and increased mortality. Use of aspirin or anticoagulants was associated with improved clinical outcomes, underscoring the importance of reinforcing thromboprophylaxis in MM patients."

Cardiovascular • Hematological Malignancies • Multiple Myeloma • Venous Thromboembolism

Risk stratification, prognostic factors, outcomes and quality of life assessment in patients with primary polycythemia (ASH 2025) - "Therapeutic modalities used at our center included phlebotomy in 91.5%, aspirin in 80.5%, cytoreduction with hydroxyurea in 25.4% and systemic anticoagulation in 11% of patients. Our study provides a valuable insight into the prognostic factors and disease process of PV and JAK2 unmutated erythrocytosis in the Indian population. It also gives a glimpse of the QoL in this population, which has till date never been explored before. With such significant divergence from global standards, it is integral to explore these in much greater detail to understand its intricacies in our large and diverse subpopulation."

Biomarker • Clinical • HEOR • Cardiovascular • Chronic Eosinophilic Leukemia • Diabetes • Dyslipidemia • Fibrosis • Hematological Disorders • Hypertension • Metabolic Disorders • Myeloproliferative Neoplasm • Polycythemia Vera • Thrombosis • JAK2

Modifiable lifestyle factors in patients with myeloproliferative neoplasms in the California teachers study (ASH 2025) - "While interventions such as therapeutic phlebotomy, aspirin, and cytoreductive therapy are helpful thrombotic risk reduction strategies, modification of cardiovascular risk factors is also recommended... The California Teacher Study MPN cohort offers longitudinal insight into the modifiable lifestyle behaviors of female patients afflicted with MPNs in California. More than a third of the cohort is overweight or obese (39.4%), suggesting weight management programs may be particularly important in this population. Alcohol consumption is present in 59.5% of the participants, which may contribute to inflammatory and thrombotic complications in MPN, suggesting that cessation may be an important modifiable risk factor in this cohort."

Clinical • Cardiovascular • Hematological Malignancies • Myelofibrosis • Myeloproliferative Neoplasm • Obesity • Polycythemia Vera • Thrombocytopenia

Application of polycythemia vera guidelines in pediatric patient with erythrocytosis: A case series (ASH 2025) - "He has been treated with aspirin and phlebotomy with significant symptom improvement...Applying adult guidelines for treatment did not show significant hematologic improvement, although symptom relief was observed in this series of patients. This series further supports the need for additional research into pediatric-specific diagnostic and management criteria for PV that incorporates clinical and genetic variability."

Clinical • Cardiovascular • Dermatology • Hypertension • Myelofibrosis • Pediatrics • Polycythemia Vera • Pruritus • Thrombocytosis • Thrombosis • BCOR • CALR • EPAS1 • JAK2 • SH2B3

Clinical characteristics and outcomes in patients with SH2B3-mutated erythrocytosis: A retrospective cohort study (ASH 2025) - "Seventy-five percent (n=12) of SH2B3 -mutated patients were on either aspirin or an anticoagulant, compared to 48% (n=270) of SE and 97% (n=100) of PV patients... We identified 16 patients with SH2B3 -mutated erythrocytosis, 103 with PV, and 566 patients with SE. Baseline hemoglobin and hematocrit at diagnosis were similar between SH2B3 -mutated, SE, and PV groups (176g/L, range 160-217; 0.53L/L, range 0.48-0.66 vs. 175g/L, range 160-246; 0.52L/L, range 0.45-0.74, vs."

Retrospective data • Cardiovascular • Hematological Malignancies • Myeloproliferative Neoplasm • Polycythemia Vera • Thrombosis • Von Hippel-Lindau Syndrome • EPOR • JAK2 • SH2B3 • VHL

Myeloproliferative neoplasms-unclassifiable (MPN-U): A carefully curated series of 30 Mayo Clinic patients (ASH 2025) - "Four (13%) patients with MPN-U experienced venous thrombo-embolic events (VTEs) including 2 with recurrent VTEs, despite active therapy with systemic anticoagulation and aspirin...Conclusion The findings from the current study were not unexpected and underline the ongoing challenges that face formal classification systems in formulating accurate diagnostic criteria for patients with MPN-U whose clinical presentation is biased by disease definitions. Regardless, it is comforting to document a favorable long-term outcome that appeared to be similar to that of ET while venous thrombosis remains a treatment challenge in both groups."

Clinical • Cardiovascular • Essential Thrombocythemia • Hematological Disorders • Myeloproliferative Neoplasm • Polycythemia Vera • Thrombocytosis • Thrombosis • ASXL1 • CALR • JAK2 • SRSF2

Potent P2Y12 Inhibitor Monotherapy vs DAPT After PCI in Patients With and Without STEMI: The NEO-MINDSET Substudy. (PubMed, J Am Coll Cardiol) - P3 | "In patients with STEMI treated with percutaneous coronary intervention, early aspirin withdrawal may be harmful, because it increases the risk of ischemic events. Conversely, in NSTE-ACS, potent P2Y12 inhibitor monotherapy may be a viable therapeutic option: Ischemic event rates were similar and bleeding was reduced compared with DAPT. (Percutaneous Coronary Intervention Followed by Antiplatelet Monotherapy in the Setting of Acute Coronary Syndromes [NEOMINDSET]; NCT04360720)."

Journal • Monotherapy • Acute Coronary Syndrome • Cardiovascular • Myocardial Infarction

A review of immunometabolic crosstalk in PCOS-related pregnancy loss: mechanisms and emerging therapeutic strategies. (PubMed, Gynecol Endocrinol) - "Both translational and clinical for interventions with dual metabolic-immune effects are highlighted, such as metformin, antioxidants likeN-acetylcysteine, anti-androgens, and combination regimens including aspirin with low-molecular-weight heparin (LMWH). PCOS-related miscarriage is increasingly recognized as resulting from dysregulation of immune-metabolic crosstalk. Mechanism-based, multidimensional strategies targeting this dual pathology represent a promising paradigm for preventing and managing pregnancy loss in women with PCOS."

Journal • Review • Genetic Disorders • Metabolic Disorders • Obesity • Polycystic Ovary Syndrome

A clinical case study: the potential impact of maternal anti-Co4 antibody on Pregnancy Conceived by in vitro fertilization (IVF) (ASH 2025) - "Due to history of aspirin intake during pregnancy, ThromboElastoGraphy (TEG 6S) with platelet mapping assay was performed to see aspirin related platelets functional defects...Since anti-Co4 antibody is exceedingly rare and no published clinical data on the outcome and adverse reactions is available, the present clinical follow up for HTR and HDFN was of utmost importance. This case is important and ubique in the sense that the pervious three reported anti-Co4 antibodies were not associated with IVF pregnancy, or HDFN as compared to our current case where both mother and baby of IVF pregnancy were at significant risk for HTR and HDFN."

Case study • Preclinical • Gynecology • AQP1

Recurrent splenic infarction in triple-positive antiphospholipid syndrome despite therapeutic anticoagulation (ASH 2025) - "She was discharged on Apixaban. This case highlights the rarity of splenic infarction as an initial presentation of triple-positive APS. Although APS is commonly associated with thromboembolic events, splenic involvement is unusual and maybe easily overlooked. The patient's progression of infarcts, despite a therapeutic INR raised concern for possible warfarin resistance, a rare but important consideration in triple-positive APS."

Atrial Fibrillation • Cardiovascular • Genetic Disorders • Hematological Disorders • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Ischemic stroke • Obstetrics • Thrombocytopenia • Vasculitis

Evolving catastrophic antiphospholipid syndrome with intracerebral hemorrhage: Treatment with plasma exchange and rituximab (ASH 2025) - "Apixaban was discontinued; enoxaparin 1 mg/kg twice daily, aspirin, prednisone 1 mg/kg with taper, and rituximab 375 mg/m² weekly ×4 were initiated...He was bridged from enoxaparin to warfarin (INR goal 2–3) for indefinite anticoagulation given APS and atrial fibrillation...Given higher recurrent thrombosis with direct oral anticoagulants reported in highrisk APS, vitamin K antagonists remain preferred for longterm therapy when feasible; multidisciplinary coordination is essential to individualize immunomodulation, anticoagulant selection, and timing. Disclaimer The views expressed in this abstract are those of the author(s) and do not necessarily reflect the official policy or position of the Defense Health Agency, the Department of Defense, or the U.S. Government."

Acute Kidney Injury • Atrial Fibrillation • Cardiomyopathy • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Complement-mediated Rare Disorders • Genetic Disorders • Hematological Disorders • Immunology • Inflammatory Arthritis • Ischemic stroke • Nephrology • Renal Disease • Thrombocytopenia • Thrombosis